In this episode, we’ll take a look at the role of Japanese pharmaceutical groups in the UK, with Jackie Davis, general manager at Astellas Pharma.Tokyo-headquartered Astellas (TYO: 4503) has developed a strong portfolio in urology, oncology and immunology, most recently with US FDA approval for Vyloy (zolbetuximab), a key addition to its cancer treatments.It’s one of many Japanese companies with a strong presence in the UK, represented nationally by the Japanese Pharmaceutical Group, of which Jackie is the current chair.We’ll get into the details of a recent visit from the JPG to the House of Lords, as well as her view on some of the challenges and opportunities that have arisen in the years since Brexit.

Ver todos los episodios